| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Feb―23 |
An evaluation of spirooxindoles as blocking agents of SARS-CoV-2 spike/ACE2 interaction: synthesis, biological evaluation and computational analysis |
Albert Enama Ehinak, Maloba M. M. Lobe, Donatus B. Eni, Conrad V. Simoben, Ian Tietjen, Mathieu J. Mbenga Tjegbe, Joel Cassel, Joseph M. Salvino, Luis J. Montaner, Wolfgang Sippl, Simon M. N. Efange, Fidele Ntie-Kang |
| 2 |
[GO] |
2024―Nov―14 |
Inhibition of SARS-CoV-2 replication in cells by G-quadruplex ligands |
Dehua Luo, Chenxi Liu, Elishiba Muturi, Zhe Hu, Wei Hong, Chao Gao, Junhua Li, Hongping Wei, Dengguo Wei, Hang Yang |
| 3 |
[GO] |
2024―Jul―14 |
Potential therapeutic effects of ester derivatives of Ribavirin against SARS-CoV-2 |
Aaminat Qureshi, Samina Bano |
| 4 |
[GO] |
2024―Jun―26 |
Design and synthesis of diphenyl-1H-imidazole analogs targeting Mpro/3CLpro enzyme of SARS-CoV-2 |
Ashish M. Kanhed, Amisha Vora, Ami Thakkar, Gudepalya Renukaiah Rudramurthy, Radha Krishan Shandil, Rajappa Harisha, Mayas Singh, Shridhar Narayanan |
| 5 |
[GO] |
2024―May―28 |
Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2 |
Roopal Garg, Raveen Kumar, Ritika Srivastava, Richa Srivastava |
| 6 |
[GO] |
2024―Mar―05 |
Design, synthesis, and biochemical and computational screening of novel oxindole derivatives as inhibitors of Aurora A kinase and SARS-CoV-2 spike/host ACE2 interaction |
Donatus B. Eni, Joel Cassel, Cyril T. Namba-Nzanguim, Conrad V. Simoben, Ian Tietjen, Ravikumar Akunuri, Joseph M. Salvino, Fidele Ntie-Kang |
| 7 |
[GO] |
2023―Dec―11 |
Computer-aided design, synthesis and evaluation of new SARS-CoV-2 Mpro inhibitors based on 1,5,6,7-tetrahydro-4H-indazol-4-one scaffold |
Yuri A. Piven, Veronica G. Zinovich, Dmitriy N. Shcherbakov, Varvara Yu. Chirkova, Svetlana V. Belenkaya, Raman M. Puzanau, Tatyana S. Khlebnicova, Fedor A. Lakhvich |
| 8 |
[GO] |
2023―Aug―10 |
Synthesis of indole-based ferulic acid derivatives and in vitro evaluation of antiviral activity against SARS-CoV-2 |
Marina Mol S. A. Verzola, Daisymara Priscila de Almeida Marques, Elany Barbosa da Silva, Mateus Sá Magalhães Serafim, Rafaela Salgado Ferreira, Pavla Fajtová, Markus Kohlhoff, Anthony John O’Donoghue, Vinícius Gonçalves Maltarollo, Jordana Grazziela Alves Coelho-dos-Reis, Renata Barbosa de Oliveira |
| 9 |
[GO] |
2023―Jul―05 |
SARS-CoV-2 3CL-protease inhibitors derived from ML300: investigation of P1 and replacements of the 1,2,3-benzotriazole |
Alice Hooper, Jonathan D. Macdonald, Brenna Reilly, Joshua Maw, Aidan P. Wirrick, Sang Hoon Han, A. Abigail Lindsey, Emma G. Rico, Todd Romigh, Christopher M. Goins, Nancy S. Wang, Shaun R. Stauffer |
| 10 |
[GO] |
2022―Aug―30 |
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations |
Ryan P. Joyce, Vivian W. Hu, Jun Wang |
| 11 |
[GO] |
2022―May―12 |
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor |
Haozhou Tan, Chunlong Ma, Jun Wang |
| 12 |
[GO] |
2022―Jan―03 |
Review on molnupiravir as a promising oral drug for the treatment of COVID-19 |
Elham Zarenezhad, Mahrokh Marzi |
| 13 |
[GO] |
2021―Dec―02 |
A review of natural products, their effects on SARS-CoV-2 and their utility as lead compounds in the discovery of drugs for the treatment of COVID-19 |
Robert L. Chapman, Shridhar V. Andurkar |
| 14 |
[GO] |
2021―Feb―05 |
Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2 |
Diego E. Escalante, David M. Ferguson |
| 15 |
[GO] |
2020―Sep―10 |
What are the drugs having potential against COVID-19? |
Kaan Kucukoglu, Nagihan Faydalı, Dilek Bul |
| 16 |
[GO] |
2020―Jul―31 |
Genomics insights of SARS-CoV-2 (COVID-19) into target-based drug discovery |
P. Chellapandi, S. Saranya |
|
